In the non-recurrent group, the following percentage of cancer cases had this double-activating KIR expression: 10/25 (40%) for rectum cancer, 5/16 (31.3%) for sigmoid cancer, 7/10 (70%) for right-sided colon cancer, and 4/7 (57.1%) for left-sided colon cancer. This evidence concerns the gene KIR3DL1 and rectal cancer.